Thermogenenic Responses to Fasting and Overfeeding in Women
University of Colorado, Denver · NCT06610162
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–65 · Women only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 56
- US sites recruiting
- 1
- Study start
- January 1, 2025
- Record last updated
- April 30, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study plans to learn more about why menopause increases the risk of weight gain. During and after menopause, women are prone to increased weight gain. The weight gained is primarily body fat, particularly visceral or abdominal body fat. The excess gain in abdominal fat during menopause increases the risk of chronic metabolic diseases such as heart disease and diabetes. The increase in weight and body fat with menopause may be due to changes in metabolism related to the loss of estrogen. This study plans to compare how the metabolism of premenopausal and postmenopausal women responds to changes in energy intake. The investigators will compare the changes in energy expenditure that occur during a period of acute fasting (24 hours) and a period of consuming excess calories (overfeeding).
Being studied: Eucalaloric feeding; Acute Fasting; Acute Overfeeding
Conditions: Obesity
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion criteria for premenopausal women
- Age 18-45 years.
- Regular menses (no missed cycles in the previous year; cycle length 25-35 d).
Inclusion criteria for postmenopausal women
- No menses for at least 12 months
- Follicular stimulating hormone (FSH) ≥50 mIU/ml.
- Women who are within 2 years of the final menstrual period are preferred
The primary exclusion criteria are
- Body mass index \> 30 kg/m2
- Diabetes (fasting glucose \>126 mg/dL).
- Thyroid dysfunction, defined as an ultrasensitive thyroid stimulating hormone (TSH) \<0.5 or \>5.0 mU/L
- Uncontrolled hypertension defined as resting systolic BP \>150 mmHg or diastolic BP \>90 mmHg.
Additional exclusion criteria for postmenopausal women
- History or current use of estrogen-based hormonal therapy
- Women who have undergone surgical menopause.
Additional exclusion criteria for premenopausal women
- Current hormonal contraceptive use (past 6 mo.).
- Pregnant, lactating, or intention to become pregnant during the study period.
Participants who fail the thyroid and BP criteria will be considered for enrollment if they receive treatment for these conditions and are considered stable by their treating physician.
Recruiting US locations
University of Colorado Anschutz Medical Campus
Aurora, CO 80045
Site contact: Edward Melanson, Ph.D. · 303-724-0935 · ed.melanson@ucdenver.edu
Study contacts (from the official record)
- Edward L Melanson, PhD · 303-724-0935 · ed.melanson@cuanschutz.edu
Similar studies in Colorado
All weight loss studies in Colorado →- RecruitingHealthy volunteersPhase 1
Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome
University of Colorado, Denver
- Location
- Aurora, CO
- Eligibility basics
- Ages 19–37 · Women only
- RecruitingPhase 3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
AstraZeneca
- Location
- Arvada, CO + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Eli Lilly and Company
- Location
- Lakewood, CO + 17 other US sites
- Eligibility basics
- Ages 18+ · Women only
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
- Location
- Aurora, CO + 59 other US sites
- Eligibility basics
- Ages 18+